Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

2231 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

2231 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

● Recruiting Phase III Respiratory / COPD / Asthma
A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
What is being tested: Tolvaptan (a vasopressin V2-receptor antagonist) is being evaluated for safety and pharmacodynamic effects in infants and children aged 28 days…
15 Jul 2026 NCT04782258
● Recruiting Phase III Diabetes / Metabolic
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
Being tested: Elecoglipron (a novel therapeutic agent) versus placebo in patients with type 2 diabetes who have impaired renal function, all receiving background dapagliflozin…
15 Jul 2026 NCT07662135
● Recruiting Phase III Diabetes / Metabolic
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
What is being tested: Ribupatide (KAI-9531), a once-weekly subcutaneous injection, is being evaluated for its efficacy in reducing body weight and improving glycaemic control…
15 Jul 2026 NCT07284901
● Recruiting Phase III Diabetes / Metabolic
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
What is being tested: The study investigates a dual-agent combination therapy of elecoglipron (a GLP-1 receptor agonist) plus dapagliflozin (an SGLT2 inhibitor) versus each…
15 Jul 2026 NCT07662109
● Recruiting Cardiology / Cardiovascular
Avr Thrombosis OutcoMe Study
What is being tested: Novel blood biomarkers that assess thrombosis and thrombolysis activity to identify patients at high risk of thrombotic complications following surgical…
15 Jul 2026 NCT04234841
● Recruiting Cardiology / Cardiovascular
“Physiological vs Right Ventricular Pacing Outcome Trial Evaluated for bradyCardia Treatment” (PROTECT-HF)
What is being tested: PROTECT-HF compares right ventricular (RV) pacing—the established standard treatment for bradycardia—against physiological pacing approaches to determine which strategy produces better…
15 Jul 2026 NCT05815745
● Recruiting Phase III Oncology
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level
What is being tested: The iFIT trial evaluates personalised treatment strategies for newly diagnosed myeloma patients who are ineligible for stem cell transplantation, with…
15 Jul 2026 NCT07649525
● Recruiting Phase III
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
A drug called zeleciment basivarsen was tested to see if it safely and effectively treats myotonic dystrophy type 1.
14 Jul 2026 NCT07486934
active not recruiting Phase II Oncology
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
Trial testing whether adding experimental drugs to tislelizumab improves outcomes in advanced head and neck cancer patients.
14 Jul 2026 NCT05909904
active not recruiting Phase I / Phase II Oncology
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
Early-stage trial testing JNJ-63723283 (anti-PD-1 antibody) to find safe doses and effectiveness across multiple advanced cancers.
14 Jul 2026 NCT02908906
active not recruiting Phase II
Study of INBRX-109 in Conventional Chondrosarcoma
Experimental drug INBRX-109 tested against placebo in patients with advanced chondrosarcoma that cannot be surgically removed.
14 Jul 2026 NCT04950075
active not recruiting Phase III Oncology
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
Durvalumab alone or combined with tremelimumab compared to chemotherapy for advanced bladder cancer.
14 Jul 2026 NCT02516241
● Recruiting Phase III
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
Eptinezumab reduced migraine days more than placebo in teenagers aged 12-17 with chronic migraine.
14 Jul 2026 NCT04965675
● Recruiting Phase III
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
Ruxolitinib cream safely and effectively treats vitiligo in children aged 6-12 years.
14 Jul 2026 NCT06804811
active not recruiting Phase III
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
A drug injected under the skin was tested to see if it could reduce kidney damage and was safe in patients with IgA nephropathy.
14 Jul 2026 NCT05248646
● Recruiting Diabetes / Metabolic
Magnetic Resonance Imaging Assessment of Multiorgan Health in Obesity
GLP-1 drugs plus lifestyle changes versus lifestyle alone for weight loss and organ health improvement in obese teenagers.
14 Jul 2026 NCT07702825
● Recruiting Phase III
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
Eptinezumab reduced migraine days in children with episodic migraine.
14 Jul 2026 NCT05897320
● Recruiting Phase III Cardiology / Cardiovascular
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
What is being tested: Elecoglipron, a novel investigational drug, is being evaluated against oral semaglutide (an established GLP-1 receptor agonist) for efficacy, safety, and…
14 Jul 2026 NCT07662213
● Recruiting Phase I Oncology
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
What is being tested: mRNA-4359, a novel immunotherapy agent, is being evaluated for safety and tolerability when administered as monotherapy and in combination with…
14 Jul 2026 NCT05533697
● Recruiting Phase I Oncology
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed
What is being tested: GSK5764227, a novel therapeutic agent, is being evaluated for safety, efficacy, and pharmacokinetics as monotherapy or in combination with other…
14 Jul 2026 NCT06885034
● Recruiting Phase III Oncology
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
What is being tested: Zanidatamab (a HER2-directed bispecific antibody) combined with standard chemotherapy (Cisplatin/Gemcitabine ± PD-1/L1 inhibitor) versus chemotherapy alone in advanced HER2-positive biliary…
14 Jul 2026 NCT06282575
active not recruiting Phase III Oncology
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
A new drug combination (ceralasertib plus durvalumab) tested against standard chemotherapy in advanced lung cancer patients whose disease progressed despite previous immunotherapy.
13 Jul 2026 NCT05450692
active not recruiting Phase III Oncology
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Trial comparing a new drug combination (Dato-DXd plus durvalumab) against standard chemotherapy plus pembrolizumab for triple-negative breast cancer.
13 Jul 2026 NCT06112379
● Recruiting
A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
Study tracking how geographic atrophy (vision loss from AMD) progresses in older adults, examining structural changes and links to genetics or lifestyle factors.
13 Jul 2026 NCT07144137
● Recruiting Phase I / Phase II Rare Diseases
A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)
LY3884961 (PR001) safety and tolerability study in adults with peripheral Gaucher disease across multiple dose levels over five years.
13 Jul 2026 NCT05487599
● Recruiting Gastroenterology
The Dirty Nappy Study
What is being tested: A machine-learning algorithm designed to automatically detect cholestasis (reduced or blocked bile flow) in newborns by analyzing patterns in clinical…
13 Jul 2026 NCT07697872
● Recruiting Oncology
TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO
What is being tested: TRACERx EVO tracks tumour evolution and genetic changes throughout treatment in patients with early- and late-stage NSCLC, SCLC, and pleural…
13 Jul 2026 NCT05628376
● Recruiting Cardiology / Cardiovascular
Comprehensive LEFt Atrial Appendage Occlusion With Rhythm Restoration
What is being tested: This trial evaluates a combined procedure using the Volt PFA System for atrial fibrillation ablation alongside the Amulet 2 device…
13 Jul 2026 NCT07523620
● Recruiting Phase IV Cardiology / Cardiovascular
Clinical Trial in Patients With Barth Syndrome- 4TAZPower
Intervention being tested: Once-daily subcutaneous injection of elamipretide in genetically confirmed Barth syndrome, evaluated over 72 weeks in a Phase 3b/4 randomised, double-blind, placebo-controlled…
13 Jul 2026 NCT07531251
● Recruiting Oncology
To Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.
What is being tested: High-resolution specimen PET-CT imaging using the XEOS AURA 10 scanner to evaluate resected cancer specimens intraoperatively, comparing imaging findings with…
13 Jul 2026 NCT06970275
● Recruiting Phase I Oncology
A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors
What is being tested: LRK-4189, an investigational agent, is being evaluated as a monotherapy and in combination regimens for treating solid tumors, with particular…
13 Jul 2026 NCT07498725
● Recruiting Phase II
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
Trial tested whether ianalumab injections could safely improve diffuse cutaneous systemic sclerosis compared to placebo.
10 Jul 2026 NCT06470048
active not recruiting Cardiology / Cardiovascular
Exploring the Long-term Cardiovascular Effects of Vaping
A two-year study comparing heart and lung function across 200 people who vape, smoke, both, or neither to assess vaping's long-term cardiovascular safety.
10 Jul 2026 NCT05757934
active not recruiting Phase III Oncology
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
Adding rilvegostomig to standard chemotherapy after biliary tract cancer surgery may improve outcomes compared to chemotherapy alone.
10 Jul 2026 NCT06109779
● Recruiting Phase II
EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety
What is being tested: Exaluren, a therapeutic agent designed to enable read-through of nonsense mutations in COL4A3/4/5 genes, is being evaluated in a randomized,…
10 Jul 2026 NCT07523581
● Recruiting Phase III Diabetes / Metabolic
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
What is being tested: Elecoglipron, a novel therapeutic agent, is being evaluated for efficacy and safety in reducing weight in adults with obesity or…
10 Jul 2026 NCT07667803
● Recruiting Phase III Cardiology / Cardiovascular
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists
What is being tested: Finerenone (a non-steroidal mineralocorticoid receptor antagonist) versus placebo in patients with heart failure and reduced ejection fraction (HFrEF) to evaluate…
10 Jul 2026 NCT06033950
● Recruiting Cardiology / Cardiovascular
Post-Market Clinical Follow Up Study With Navitor Valve
What is being tested: The Navitor TAVI (Transcatheter Aortic Valve Implantation) System is undergoing post-market evaluation to assess its safety profile and clinical performance…
10 Jul 2026 NCT06008080
● Recruiting Phase II Cardiology / Cardiovascular
Comparative Evaluation of Sustained meChanical AsPiration Thrombectomy and no Thrombus Modification for Pre-stent Thrombus bUrden Reduction in Patients With Acute Myocardial Infarction Study: the CAPTURE AMI Study
Treatment being tested: Sustained mechanical aspiration thrombectomy versus standard percutaneous coronary intervention (PCI) without thrombus modification in STEMI patients with angiographically confirmed high thrombus…
10 Jul 2026 NCT07687576
● Recruiting Phase I Oncology
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
LY4152199 is a novel investigational agent being evaluated for dose-optimisation, safety, and efficacy in patients with relapsed or refractory B-cell malignancies who have failed…
10 Jul 2026 NCT07101328
active not recruiting Phase III Oncology
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)
Osimertinib continuation study for cancer patients benefiting from treatment in previous trials.
09 Jul 2026 NCT05629234
● Recruiting Infectious Disease
Clinical Outcomes Study of the Nexel Total Elbow
Nexel Total Elbow implant study confirms it's safe and works well for new and repeat elbow replacement surgery.
09 Jul 2026 NCT02469662
active not recruiting Phase III Diabetes / Metabolic
Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism
Long-term safety study of dasiglucagon injections in children with congenital hyperinsulinism, following earlier trial completion. (Word count: 19)
09 Jul 2026 NCT03941236
active not recruiting Phase III
Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials
Patients who received OAV101 for spinal muscular atrophy are being monitored for five years to check long-term safety and effectiveness.
09 Jul 2026 NCT05335876
● Recruiting Phase II Cardiology / Cardiovascular
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
What is being tested: CDR132L, a novel therapeutic agent, is being evaluated at different doses versus placebo to assess its effects on cardiac structure…
09 Jul 2026 NCT06979362
● Recruiting Phase II Oncology
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
What is being tested: Telisotuzumab adizutecan (a novel targeted therapy) combined with standard chemotherapy (oxaliplatin, fluorouracil, folinic acid), bevacizumab, and panitumumab in metastatic colorectal…
09 Jul 2026 NCT06820463
● Recruiting Phase I Oncology
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
What is being tested: ORIC-944, a novel therapeutic agent, is being evaluated both as monotherapy and in combination with androgen receptor pathway inhibitors (ARPIs)…
09 Jul 2026 NCT05413421
● Recruiting
Registry for Patients With X-Linked Hypophosphatemia
What is being tested: This international prospective registry collects observational data on treatment patterns, disease progression, and long-term outcomes in patients with X-Linked Hypophosphatemia…
09 Jul 2026 NCT03193476
● Recruiting Phase II Oncology
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
What is being tested: Telisotuzumab adizutecan (a novel antibody-drug conjugate targeting HER3) administered intravenously as monotherapy or combined with osimertinib (EGFR tyrosine kinase inhibitor),…
09 Jul 2026 NCT07155187
● Recruiting Phase I Oncology
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
NXP900 is a first-in-human investigational agent being tested in a dose escalation and expansion study to determine safety, tolerability, and optimal dosing in patients…
09 Jul 2026 NCT05873686